Despite the huge effort and massive advances toward the elimination of leprosy over the last two decades, the disease has proven stubborn; new case detection rates have stabilised over the last few years and leprosy remains endemic in a number of localised regions. The American Leprosy Missions and Infectious Disease Research Institute have undertaken a large research effort aimed at developing new tools and a vaccine to continue the push for leprosy elimination. In this paper, we outline our strategy for the integration of rapid diagnostic tests and lab-based assays to facilitate the detection of early or asymptomatic leprosy cases, as well as the efficient and focused implementation of chemoprophylaxis and immunisation to intervene in leprosy development and transmission.

Leprosy is a slowly evolving disease that occurs mainly in adults. In this study, the Mamaría Village, state of Portuguesa was selected because it had one of the highest prevalence rates (13.25%) of leprosy cases in 1997. Between 1998-2004, 20.2% of the 89 cases registered in this village were less than 15 years old and 61.8% were males. Pau-cibacillary (PB) lesions were the predominant clinical forms identified, although also multibacillary (MB) forms were found. Additionally, 76% of the patients were bacteriologically negative. At the time of diagnosis, 75% of the patients presented with grade 0 disabilities, 23% with grade 1 and 2% with grade 2. Serum samples were collected from 18 PB and 15 MB patients, in addition to 14 family contacts, at the beginning and end of treatment. All the groups were re-evaluated during a three-year period (2008-2011). The proteins used for evaluation were ML0405, ML2331 and LID-1. These mycobacterial proteins were highly specific for Mycobacterium leprae and the IgG responses decreased in both MB and PB patients during multidrug treatment. Our results suggest that these antigens could be used as markers for successful treatment of non-reactional lepromatous patients.

New Mycobacterium leprae protein antigens can contribute to improved serologic tests for leprosy diagnosis/classification and multidrug therapy (MDT) monitoring. This study describes seroreactivity to M. leprae proteins among participants from three highly endemic leprosy areas in Brazil: central-western Goiânia/Goiás (GO) (n = 225), Rondonópolis/Mato Grosso (MT) (n = 764) and northern Prata Village/Pará (PA) (n = 93). ELISA was performed to detect IgG to proteins (92f, 46f, leprosy IDRI diagnostic-1, ML0405, ML1213) and IgM to phenolic glycolipid-I (PGL-I). Multibacillary (MB) leprosy had positive rates for PGL-I that were similar to those for proteins; however, some anti-PGL-I-negative subjects were positive for proteins, suggesting that adding protein antigen to PGL-I can enhance the sensitivity of MB leprosy detection. In MT, different degrees of seroreactivity were observed and ranked for MB, former patients after MDT, paucibacillary (PB) leprosy, household contact (HHC) and endemic control (EC) groups. The seroreactivity of PB patients was low in GO and MT. HHCs from different endemic sites had similar IgG antibody responses to proteins. 46f and 92f were not recognised by most tuberculosis patients, ECs or HHCs within GO, an area with high BCG vaccination coverage. Low positivity in EC and HHC was observed in PA and MT. Our results provide evidence for the development of an improved serologic test that could be widely applicable for MB leprosy testing in Brazil.

Sixty-five patients were diagnosed with visceral leishmaniasis (VL) on Margarita Island in the decade from 1990 to1999; 86.2% were <= 3 years old. All were leishmanin-negative at diagnosis. Evaluation of 23 cured patients in 1999 revealed that 22/23 had converted to leishmanin-positive; five had persisting antibodies to rK39 antigen, with no clinical evidence of disease. Leishmanin tests were positive in 20.2% of 1,643 healthy individuals from 417 households in endemic areas. Of the positive reactors, 39.8% were identified in 35 (8.4%) of the households, 15 of which had an antecedent case of VL, a serologically positive dog or both. Weak serological activity to rK39 antigen was detected in 3 of 488 human sera from the endemic areas. The presence of micro-foci of intense peri-urban transmission and the apparent absence of other Trypanosomatidae causing human disease offer a unique opportunity for the study of reservoirs, alternative vectors and evaluation of control measures on the Island.

Immunotherapy has been proposed as a method to treat mucosal leishmaniasis for many years, but the approach has been hampered by poor definition and variability of antigens used, and results have been inconclusive. We report here a case of antimonial-refractory mucosal leishmaniasis in a 45 year old male who was treated with three single injections (one per month) with a cocktail of four Leishmania recombinant antigens selected after documented hypo-responsiveness of the patient to these antigens, plus 50mg of GM-CSF as vaccine adjuvant. Three months after treatment, all lesions had resolved completely and the patient remains without relapse after two years. Side effects of the treatment included only moderate erythema and induration at the injection site after the second and third injections. We conclude that carefully selected microbial antigens and cytokine adjuvant can be successful as immunotherapy for patients with antimonial-refractory mucosal leishmaniasis.

O emprego de esfregaços por aposição (imprint), cortes histológicos e inóculo em hamster foram, em conjunto, capazes de detectar Leishmania em 71,2% de pacientes com acometimento cutâneo e 48% com acometimento da mucosa. Os parasitos eram mais freqüentes em lesões cutâneas recentes (p. < 0,005) do que após dois meses de duração. Também eram mais freqüentes em lesões múltiplas da mucosa do que naquelas isoladas (p < 0,02) embora o primeiro grupo tivesse recebido anteriormente terapia por glucantime. 93% dos pacientes com lesões cutâneas tiveram o teste de leishmania positivo sendo que a maioria dos casos negativos ocorreu em pacientes cujas lesões tinham menos de um mês de duração. 97% dos pacientes com uma única lesão da mucosa e 79% daqueles com múltiplas lesões foram positivos para o teste de leishmanina. O teste de imunofluorescência indireta apresentou positividade em diluições de 1:20 em 86% dos casos de acometimento cutâneo e 90% daqueles de acometimento da mucosa. Nos dois grupos as lesões múltiplas estavam associadas com os títulos mais altos e estes eram significativamente mais altos nos pacientes com acometimentos da mucosa quando comparados com os casos de compromentimento cutâneo p^0,01).

Leishmanial parasites were detected in 71.2% of patients with cutaneous disease and 48% of patients with mucosal disease, using principally scanning of imprints mears and histological sections and hamster inoculation. Parasites were more frequent in early cutaneous lesions (p < 0.005) o fless than two month duration. Also they were more common in multiple than single mucosal lesions (p < 0.02) in spite of considerable prior glucan time therapy in the former group. 93% of cutaneous lesions had a positive leishmanin skin test and most of the negatives occurred in patients with lesions of less than one month duration. 97% of patients with single mucosal lesion and 79% with multiple mucosal lesions had a positive skin test. 86% of cutaneous disease and 90% of mucosal disease was associated with a positive indirect immunofluorescent antibody test at a ≥ 1/20 dilution. In both groups multiple lesions were associated with higher titres and titres were significantly higher in patients with mucosal disease compared with cutaneous disease (p < 0.01).

Um estudo histopatológico e ultraestrutural das lesões da leishmaniose cutânea causada pela Leishmania mexicana amazonensis em duas cepas isogênicas de camundongo, uma susceptível (Balb/c) e outra resistente (A/J), demonstrou que os amastigotas ficavam bem preservados nos vacúolos parasitóforos dos macrófagos, igualmente em ambas as cepas. A reação de imunofluorescência revelou antigenos parasitários no interior e na membrana dos macrófagos de maneira idêntica para ambas as cepas. A diferença ocorria quando os macrófagos apareciam destruídos e as leishmanias ficavam livres ou fagocitadas por polimorfonucleares, neutrófilos e eosinófilos. Estes parasitos exibiam então graus variáveis de nítidas alterações degenerativas. No camundongo resistence, a necrose, de tipo caseoso ou fibrinóide, era mais disseminada e mais freqüente que no animal susceptível. Os achados observados indicaram que as leishmanias não são destruídas no interior dos macrófagos e sim fora deles, especialmente quando fagocitadas por leucócitos polimorfonucleares. A necrose apareceu como o mecanismo mais saliente através do qual o hospedeiro elimina os parasitos das lesões, sendo a mesma um aspecto importante da reação de hipersensibilidade tardia que ocorre nos animais resistentes.

Amastigotes of Leshmania mexicana amazonensis appeared healthy and well preserved within the parasitophorous vacuoles of macrophages during the infection of a susceptible (Balb/c) or a relatively resistant (A/J) inbred strain of mice. Immunofluorescence showed the presence of leishmanial antigens within infected macrophages and in their external membranes similar for both strains. When the amastigotes were found extracellularly or within polymorphonuclear neutrophils or eosinophils, marked ultrastructural degenerative changes were observed in them. Such necrotic alterations were seen frequently in the resistant mice and rarely in the susceptible ones. Thus, necrosis of parasitized macrophages appeared as a major mechanism through which the resistant host eliminates the parasites from the lesions. It may be considered as a histological marker of resistance in leishmaniasis and represents a prominent component of the delayed-type immunological mechanism occurring in resistant hosts.